Research in the microbiome-targeted therapeutics has been in the news for some time, so the latest report from a leading data and analytics company is a timely look at some of the players.
With smaller biotech companies dominating the pipeline for microbiome-targeted therapeutics, large pharma firms, such as Johnson & Johnson (NYSE: JNJ), are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology, according to GlobalData.
The company’s report, titled Microbiome-Targeted Therapeutics in Immunology, focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis, and on treatments targeting the gut microbiome for the treatment of Crohn’s disease, ulcerative colitis and irritable bowel syndrome (IBS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze